Back to top
more

Alnylam Pharmaceuticals (ALNY)

(Real Time Quote from BATS)

$423.96 USD

423.96
478,142

+5.05 (1.21%)

Updated Aug 6, 2025 01:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss

by Zacks Equity Research

Novo Nordisk stock gains as its subcutaneous investigational candidate, amycretin, achieves superior weight loss compared to placebo in an obesity study.

Zacks Equity Research

New Strong Buy Stocks for January 27th

by Zacks Equity Research

ALNY, HBT, APH, GNTY and OSUR have been added to the Zacks Rank #1 (Strong Buy) List on January 27, 2024.

Zacks Equity Research

RDY Q3 Earnings Match Estimates, Generics Revenues Rise Y/Y, Stock Down

by Zacks Equity Research

Dr. Reddy's stock falls on Q3 fiscal 2025 results, wherein earnings match estimates but revenues beat the same.

Zacks Equity Research

Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why

by Zacks Equity Research

AVXL stock soars 95% in three months on positive updates from the development programs of its two clinical candidates, blarcamesine and ANAVEX 3-71.

Zacks Equity Research

GILD vs. ALNY: Which Stock Is the Better Value Option?

by Zacks Equity Research

GILD vs. ALNY: Which Stock Is the Better Value Option?

Zacks Equity Research

Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Best Momentum Stocks to Buy for January 21st

by Zacks Equity Research

CDNA, AVXL and ALNY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 21, 2025.

Zacks Equity Research

Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year?

by Zacks Equity Research

Here is how Alnylam Pharmaceuticals (ALNY) and Medpace (MEDP) have performed compared to their sector so far this year.

Zacks Equity Research

New Strong Buy Stocks for January 21st

by Zacks Equity Research

CDNA, ALNY, ICL, AVXL and AA have been added to the Zacks Rank #1 (Strong Buy) List on January 21, 2025.

Zacks Equity Research

ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals

by Zacks Equity Research

Alnylam reports preliminary fourth-quarter and full-year 2024 product revenues. The company expects to deliver adjusted operating income profitability in 2025.

Zacks Equity Research

Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Alnylam Pharmaceuticals (ALNY) and argenex SE (ARGX) have performed compared to their sector so far this year.

Zacks Equity Research

The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam

by Zacks Equity Research

Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam are included in this Analyst Blog.

Ekta Bagri headshot

4 Biotech Stocks Most Wall Street Analysts Are Bullish About

by Ekta Bagri

Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundamentals.

Zacks Equity Research

CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study

by Zacks Equity Research

Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients.

Zacks Equity Research

QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug

by Zacks Equity Research

uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.

Zacks Equity Research

FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD

by Zacks Equity Research

The FDA accepts GSK's regulatory filing seeking the expanded use of Nucala in COPD treatment for review.

Zacks Equity Research

TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy

by Zacks Equity Research

Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder cancer study.

Zacks Equity Research

What Makes Alnylam (ALNY) a New Buy Stock

by Zacks Equity Research

Alnylam (ALNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Sensus Healthcare, Inc. (SRTS) and Alnylam Pharmaceuticals (ALNY) have performed compared to their sector so far this year.

Zacks Equity Research

Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for QQQJ

Zacks Equity Research

BridgeBio Stock Up on FDA Approval of Cardiovascular Drug

by Zacks Equity Research

BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.

Zacks Equity Research

FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use

by Zacks Equity Research

ALNY reports submitting an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.

Zacks Equity Research

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Zacks Equity Research

ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study

by Zacks Equity Research

Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose.

Zacks Equity Research

AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down

by Zacks Equity Research

Agios' third-quarter 2024 earnings miss estimates while revenues match the same. Shares fall.